Biomea Fusion (BMEA) vs Conexeu Sciences (CNXU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biomea Fusion is the larger company by market cap ($99.1 million vs $97.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | CNXU |
|---|---|---|
| Share price | $1.37 | $3.45 |
| Market cap | $99.05M | $97.31M |
| 1-day change | +3.79% | -5.22% |
| YTD return | +10.48% | — |
| 1-year return | -18.45% | — |
| 5-year return | -88.22% | — |
| EPS (TTM) | $-0.30 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.24 | $18.79 |
| 52-week low | $0.872 | $3.05 |
| Distance from 52-week high | -38.76% | -81.64% |
| Analyst consensus | buy | none |
| Avg. price target upside | +410.95% | +479.71% |
| Average volume | 1.47M | 203.38K |
| Shares outstanding | 72.30M | 28.21M |
| Employees | 37 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Healthcare · Biotechnology · 37 employees
About Conexeu Sciences
CNXU stock →Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair.
Healthcare · Biotechnology
BMEA vs CNXU FAQ
Which is bigger, Biomea Fusion or Conexeu Sciences?
Biomea Fusion (BMEA) is larger, with a market capitalization of $99.05M compared with $97.31M for Conexeu Sciences (CNXU).
Are Biomea Fusion and Conexeu Sciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.